



Cholestenone functions as an antibiotic against *Helicobacter pylori* by inhibiting biosynthesis of the cell wall component CGL

Junichi Kobayashi^{a,b,1}, Masatomo Kawakubo^{a,1}, Chifumi Fujii^{a,c}, Nobuhiko Arisaka^a, Masaki Miyashita^a, Yoshiko Sato^a, Hitomi Komura^a, Hisanori Matoba^a, and Jun Nakayama^{a,2}

^aDepartment of Molecular Pathology, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan; ^bDepartment of 2nd Internal Medicine, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan; and ^cDepartment of Biotechnology, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Asahi 3-1-1, Matsumoto 390-8621, Japan

Edited by Staffan Normark, Karolinska Institute, Stockholm, Sweden, and approved March 9, 2021 (received for review August 4, 2020)

Helicobacter pylori, a pathogen responsible for gastric cancer, contains a unique glycolipid, cholesteryl- α -D-glucopyranoside (CGL), in its cell wall. Moreover, O-glycans having α 1,4-linked N-acetylglucosamine residues (α GlcNAc) are secreted from gland mucous cells of gastric mucosa. Previously, we demonstrated that CGL is critical for *H. pylori* survival and that α GlcNAc serves as antibiotic against *H. pylori* by inhibiting CGL biosynthesis. In this study, we tested whether a cholesterol analog, cholest-4-en 3-one (cholestenone), exhibits antibacterial activity against *H. pylori* in vitro and in vivo. When the *H. pylori* standard strain ATCC 43504 was cultured in the presence of cholestenone, microbial growth was significantly suppressed dose-dependently relative to microbes cultured with cholesterol, and cholestenone inhibitory effects were not altered by the presence of cholesterol. Morphologically, cholestenone-treated *H. pylori* exhibited coccoid forms. We obtained comparable results when we examined the clarithromycin-resistant *H. pylori* strain "2460." We also show that biosynthesis of CGL and its derivatives cholesteryl-6-O-tetradecanoyl- α -D-glucopyranoside and cholesteryl-6-O-phosphatidyl- α -D-glucopyranoside in *H. pylori* is remarkably inhibited in cultures containing cholestenone. Lastly, we asked whether orally administered cholestenone eradicated *H. pylori* strain SS1 in C57BL/6 mice. Strikingly, mice fed a cholestenone-containing diet showed significant eradication of *H. pylori* from the gastric mucosa compared with mice fed a control diet. These results overall strongly suggest that cholestenone could serve as an oral medicine to treat patients infected with *H. pylori*, including antimicrobial-resistant strains.

antimicrobial resistance | glycolipid | eradication | *Helicobacter pylori*

Helicobacter pylori is a gram-negative microaerophilic pathogen that colonizes the human stomach in approximately half the world's population. It is well established that *H. pylori* infection is closely associated with pathogenesis of chronic active gastritis, peptic ulcer, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma (1–4). Thus, in 1994, *H. pylori* was categorized as a Group I carcinogen by the World Health Organization's International Agency for Research on Cancer. Accordingly, eradication therapy for *H. pylori* is expected to decrease the incidence of gastric cancer (5–7). In fact, eradication of the bacterium has been successfully achieved in ~90% of infected patients using a combination of three drugs, namely, a proton pump inhibitor (PPI), clarithromycin, and amoxicillin (8, 9). However, successful eradication has been challenged by emergence of drug-resistant strains, in particular, clarithromycin-resistant *H. pylori* (10). Thus, development of new strategies as eradication therapy for *H. pylori* including drug-resistant strains is needed.

The cell wall of *Helicobacter* species, including *H. pylori*, characteristically contains unique glycolipid α -cholesteryl glucosides (α CGs), of which the major components are cholesteryl- α -D-glucopyranoside (CGL), cholesteryl-6-O-tetradecanoyl- α -D-glucopyranoside (CAG), and cholesteryl-6-O-phosphatidyl- α -D-glucopyranoside (CPG) (11). α CGs are synthesized by cholesterol α -glucosyltransferase

(α CgT), which transfers glucose from UDP-glucose to a carbon atom at the third position of cholesterol with an α 1,3-linkage (SI Appendix, Fig. S1A). On the other hand, gastric gland mucous cells secrete unique O-glycans having terminal α 1,4-linked N-acetylglucosamine (α GlcNAc) attached to the scaffold protein MUC6. Previously, we revealed that α GlcNAc suppresses *H. pylori* growth by inhibiting α CgT activity, which forms CGL (12, 13). Because the *H. pylori* genome does not encode enzymes required for cholesterol biosynthesis, microbes require exogenous cholesterol to synthesize α CGs (14, 15).

Cholestenone is a cholesterol analog catabolized from cholesterol by intestinal bacteria, including human-derived *Escherichia coli*, *Eubacterium*, and *Bacteroides* sp. that replace the steroid β -hydroxyl group with a keto group (16–20). Because the hydroxyl group at the cholesterol third position is critical to form CGL, we hypothesized that cholestenone cannot serve as an α CgT substrate (SI Appendix, Fig. S1B) and thus that cholestenone treatment could inhibit *H. pylori* growth due to defective CGL biosynthesis.

In the present study, we examined growth capacity of *H. pylori* in vitro in the presence of cholesterol and analogs including cholestenone, β -sitosterol, and cholestanol (SI Appendix, Fig. S2). Our results clearly indicate that growth of *H. pylori*, including that of a clarithromycin-resistant strain, was significantly suppressed by cholestenone through inhibition of CGL biosynthesis. When

Significance

Cholesteryl- α -D-glucopyranoside (CGL) is a cell wall constituent of *Helicobacter pylori*. It is synthesized by cholesterol α -glucosyltransferase, which transfers glucose from UDP-glucose to a carbon atom at the third position of cholesterol with an α 1,3-linkage. We previously discovered that α GlcNAc contained in gastric gland mucins serves as antibiotic against *H. pylori* by inhibiting CGL biosynthesis. Here, we reveal that cholestenone exhibits antibiotic activity against *H. pylori* including a clarithromycin-resistant *H. pylori* strain by suppressing CGL biosynthesis in vitro. Strikingly, oral administration of cholestenone alone successfully eradicated *H. pylori* infection in C57BL/6 mice. Given its safety, cholestenone therapy could be promising to eradicate *H. pylori*, including antibiotic-resistant strains.

Author contributions: M.K. and J.N. designed research; J.K., M.K., C.F., N.A., M.M., Y.S., H.K., and H.M. performed research; J.K., M.K., and J.N. analyzed data; and J.K., M.K., and J.N. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

Published under the PNAS license.

¹J.K. and M.K. contributed equally to this work.

²To whom correspondence may be addressed. Email: jnakayama@shinshu-u.ac.jp.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2016469118/-DCSupplemental>.

Published April 14, 2021.

cholestenone was orally administered to *H. pylori*-infected C57BL/6 mice, mice showed successful eradication of the microbe. Because cholestenone is safe, therapy using cholestenone could be a promising approach to eliminate *H. pylori* infection in humans, including infection with antibiotic-resistant strains.

Results

Incorporation of Cholesterol into *H. pylori*. Because *H. pylori* cannot synthesize cholesterol, microbes require exogenous cholesterol to synthesize CGL required for bacterial growth (12). However, actually incorporated cholesterol into *H. pylori* had not been visualized. To visualize exogenous cholesterol incorporation into the cell wall, we grew microbes in cultivation broth containing the fluorocholesterol, TopFluor cholesterol, rather than cholesterol (SI Appendix, Fig. S3). *H. pylori* cultured with TopFluor cholesterol grew well, but the growth rate was significantly lower than that seen in the presence of cholesterol (Fig. 1A). Using fluorescent microscopy, we detected incorporation of TopFluor cholesterol into the *H. pylori* cell wall, and the relative number of *H. pylori* incorporating TopFluor cholesterol increased with days in culture (Fig. 1B). These results indicate that *H. pylori* incorporates exogenous fluorocholesterol.

Effects of Cholesterol Derivatives on *H. pylori* Growth. We hypothesized that a hydroxyl group at the third position of the cholesterol carbon atom was critical to form CGL, which is essential for *H. pylori* survival (SI Appendix, Fig. S1), as α -glucose is attached to this site. To test this hypothesis, we used three kinds of sterol derivatives, including cholestenone, cholestanol, and β -sitosterol, as supplements for *H. pylori* (ATCC 43504) culture. Among them, cholestenone has a keto group at the third position of carbon atom, while both cholestanol and β -sitosterol have a hydroxyl group at that position (SI Appendix, Fig. S2). As a positive control, we employed cholesterol as a supplement. Most rewarding, *H. pylori* growth was markedly suppressed in the presence of cholestenone (Fig. 2A), and microbial shape changed from a normal spiral form to a coccoid form, a transformation evident by day 2 of culture (Fig. 2B). By contrast, *H. pylori* cultured with cholestanol or β -sitosterol grew as well as microbes grown in cholesterol (Fig. 2A). We observed similar effects on bacterial proliferation and morphology when we tested various cholesterol derivatives using the

clinically isolated *H. pylori* strain “2460,” which is resistant to clarithromycin (Fig. 2C and D). These results suggest that cholestenone inhibits *H. pylori* growth, most likely by blocking CGL biosynthesis.

Growth Inhibitory Effects of Cholestenone in Presence of Cholesterol.

H. pylori attaches to surface mucous cells, which contain cholesterol (21). Thus, we asked whether cholestenone would inhibit growth of *H. pylori* growth cultured in medium containing an equal concentration of cholesterol. As shown in Fig. 3A, growth of the *H. pylori* standard strain ATCC 43504 was significantly inhibited by 150 μ M cholestenone, either with or without the same concentration of cholesterol (Fig. 3A). Such inhibitory effects were also observed dose-dependently at day 4 of a 4 d culture at cholestenone concentrations ranging from 4.7 to 150 μ M in the presence of 150 μ M cholesterol (Fig. 3B). We then tested cholestenone antimicrobial effects using a clinically isolated *H. pylori* strain “2460” resistant to clarithromycin. Surprisingly, over a 4 d culture period, inclusion of 150 μ M cholestenone in media suppressed microbial growth irrespective of the presence or absence of the same concentration of cholesterol, an effect that was significant except at day 2 of culture. (Fig. 3C). Moreover, in the presence of 150 μ M cholesterol, inclusion of cholestenone in medium had an overall dose-dependent inhibitory effect on growth at concentrations ranging from 4.7 to 150 μ M (Fig. 3D).

H. pylori Cultured with Cholestenone Show Reduced CGL Expression.

To determine whether cholestenone suppressed CGL biosynthesis, we analyzed lipid fractions extracted from *H. pylori* cultured 2 d with cholesterol or cholestenone by thin-layer chromatography. *H. pylori* (ATCC 43504) cultured with standard medium containing 10% inactivated horse serum exhibited three distinct bands representing CGL and its derivatives CAG and CPG (Fig. 4A). When *H. pylori* was cultured with cholesterol, we detected bands representing CGL and CAG. However, relative to levels seen in the presence of cholesterol, CGL and CAG levels were significantly decreased in *H. pylori* cultured with cholestenone (Fig. 4A). We also observed relatively reduced CGL expression in *H. pylori* cultured with cholestenone based on immunocytochemistry with a newly generated anti-CGL antibody, which we validated using an antigen adsorption test (Fig. 4B). Prior to that, immunocytochemistry with commercially available anti-*H. pylori* antibody revealed that *H. pylori* (ATCC 43504) cultured 4 d with inactivated horse serum or cholesterol




Fig. 1. Cholesterol incorporation into *H. pylori*. (A) Growth curves of *H. pylori* (ATCC 43504) in media containing cholesterol (circles) or the fluorocholesterol TopFluor cholesterol (squares). Assay was done in triplicate, and error bars indicate SE (* $P < 0.05$, ** $P < 0.01$). (B) Fluorescence microscopy of *H. pylori* (ATCC 43504) cultured as indicated over 4 d (Scale bar, 5 μ m).




Fig. 2. Growth curves and morphology of *H. pylori* cultured with various sterols. (A) Growth curves of a standard *H. pylori* strain (ATCC 43504) cultured in medium supplemented with 150 μ M indicated sterols. Each value represents the average of triplicate measurements, and error bars indicate SE. Statistical analysis was performed using cholesterol as a reference (* $P < 0.05$, ** $P < 0.01$). (B) Morphology of *H. pylori* (ATCC 43504) cultured with indicated sterols over a 4 d culture period. Immunocytochemistry was performed using an anti-*H. pylori* antibody (Scale bar, 2 μ m). (C) Growth curves of the clarithromycin-resistant strain *H. pylori* ("2460") cultured in medium supplemented with 150 μ M indicated sterols. Each value represents the average of triplicate measurements, and error bars indicate SE. Statistical analysis was performed using cholesterol as a reference (* $P < 0.05$). (D) Morphology of *H. pylori* ("2460") cultured with indicated sterols over a 4 d culture period. Immunocytochemistry was performed using an anti-*H. pylori* antibody (Scale bar, 2 μ m).

exhibited the typical spiral form, whereas *H. pylori* cultured with cholestenone exhibited a coccoid form (Fig. 4B). When microbes in this analysis were immunostained with anti-CGL antibody, expression levels of CGL in coccoid forms of *H. pylori* cultured with cholestenone were reduced compared with spiral forms of the microbe cultured with cholesterol (Fig. 4B). These combined results strongly suggest that cholestenone suppresses CGL biosynthesis.

Kobayashi et al.
Cholestenone functions as an antibiotic against *Helicobacter pylori* by inhibiting biosynthesis of the cell wall component CGL

In Vivo Effects of Cholestenone Administration in *H. pylori*-Infected Mice. To determine whether orally administered cholestenone would eliminate *H. pylori* in vivo, we orally infected 5-wk-old C57BL/6 mice ($n = 54$) with two doses of 3×10^7 *H. pylori* strain SS1 and then, starting a week later, fed them ad libitum with food pellets with or without 0.5% (wt/wt) cholestenone until 10 wk of age (Fig. 5A). At 10 wk of age, stomachs were removed from both cholestenone (+) and (-) groups. We then determined the number




Fig. 3. Effects of cholesterol and cholestenone on *H. pylori* growth. (A) Growth curves of a standard *H. pylori* strain (ATCC 43054) cultured in medium supplemented with either 150 μ M cholesterol, 150 μ M cholestenone, or both. Assay was done in triplicate, and error bars indicate SE. Statistical analysis was performed based on cholesterol values (** $P < 0.01$). (B) Growth curves of *H. pylori* ATCC 43054 strain cultured for 4 d in medium supplemented with 150 μ M cholesterol plus concentrations of cholestenone ranging from 4.7 to 150 μ M. All assays were done in triplicate, and error bars indicate SE. (C) Growth curves of a clarithromycin-resistant strain *H. pylori* "2460" cultured in medium supplemented with either 150 μ M cholesterol, 150 μ M cholestenone, or both. Assay was done in triplicate, and error bars indicate SE. Statistical analysis was performed based on cholesterol values (** $P < 0.01$). (D) Growth curves of the *H. pylori* "2460" strain cultured for 4 d in medium supplemented with 150 μ M cholesterol plus concentrations of cholestenone ranging from 4.7 to 150 μ M. All assays were done in triplicate, and error bars indicate SE.

of *H. pylori* in stomach using qPCR of DNA harboring the *H. pylori* α CgT gene, which encodes cholesterol α CgT that catalyzes CGL biosynthesis (22–24). The copy number of α CgT ranged from 0 to 45.6 copies (median [25th to 75th percentile] = 2.65 [0.91 to 8.13]) per 1 mg gastric mucosa in the cholestenone (–) group ($n = 24$) and ranged from 0 to 9.1 copies (0.00 [0.00 to 0.10]) per the same weight of gastric mucosa in the cholestenone (+) group ($n = 24$) (Fig. 5B). Because α CgT is a single-copy gene in the microbe, we conclude that the number of *H. pylori* in the cholestenone (+) group was significantly lower than that in the cholestenone (–) group ($P < 0.01$). These results establish that 4 wk of dietary cholestenone administration successfully eradicates *H. pylori* infected in the gastric mucosa of mice. Histopathological examination of the gastric mucosa showed no obvious histopathological findings in all mice

($n = 6$), including three mice in the cholestenone (–) group and three mice in the cholestenone (+) group (Fig. 5C).

Discussion

Here, we report that cholestenone suppresses *H. pylori* growth via a mechanism distinct from that of clarithromycin or amoxicillin, which are generally used for *H. pylori* eradication. Specifically, clarithromycin inhibits peptide translation, and amoxicillin inhibits peptidoglycan biosynthesis in the cell wall (25). Hirai et al. reported that *H. pylori* exhibits the unique glycolipids CGL, CAG, and CPG, which make up about 25% of total lipid (11). *H. pylori* can be grown in liquid cultures containing Columbia broth, Brain Heart infusion broth, or Brucella broth, all enriched with inactivated horse serum (26). *H. pylori* incorporates exogenous cholesterol contained in all of these media to form CGL as a cell wall




Fig. 4. Cholestenone treatment reduces CGL expression in *H. pylori*. (A) Thin layer chromatogram of α CGs isolated from *H. pylori* (ATCC 43054) cultured with supplements including inactivated horse serum (as a control) or cholesterol or cholestenone, as indicated. (B) Morphology of *H. pylori* cultured with various supplements. *H. pylori* (ATCC 43054) was immunostained with anti-CGL antibody (Upper, first three panels) or anti-*H. pylori* antibodies (Lower, first three panels). Also shown is staining with secondary antibody (Histofine Simple Stain MAX-PO[R] Kit) alone (Upper and Lower, panel 4). Immunocytochemistry of *H. pylori* (ATCC 43504) incubated in Brucella broth was supplemented with 10% inactivated horse serum at 35 °C in 15% CO₂ for 24 h with anti-CGL antibody preincubated with 0.75 μ M of oxidized CGL as hapten is shown as antigen adsorption (Upper, panel 5) (Scale bar, 2 μ m).

component, and CGL is critical for *H. pylori* survival (27). Previously, we found that *H. pylori* can grow well with exogenous cholesterol but poorly in serum-free medium (12). Despite the fact that *H. pylori* requires cholesterol to construct its cell membrane (13), *H. pylori* does not possess a cholesterol biosynthetic pathway (14, 15, 28, 29). Here, we supplemented culture medium with fluorescent cholesterol and found it incorporated into *H. pylori* (Fig. 1B). We also demonstrated that cholestenone inhibited biosynthesis of CGL and its derivatives CAG and CPG (Fig. 4A). Cholestenone inhibition of *H. pylori* growth was also associated with the coccoid form of the microbe (Fig. 2B), a morphological transformation also seen in α CgT-deficient *H. pylori* (30). It is well known that like spiral forms, coccoid forms of *H. pylori* are viable, but unlike spiral forms, coccoid forms are nonculturable and relatively less virulent (31). Notably, Eaton et al. revealed that coccoid forms of *H. pylori* cannot colonize gnotobiotic piglets, unlike spiral forms (32). These results combined together strongly suggest that *H. pylori* cultured with cholestenone is nonvirulent and loses infectivity.

The present study demonstrated that cholestenone displayed remarkable antibiotic activity against *H. pylori*, even in the presence of cholesterol (Fig. 3). We previously reported that α CgT acts in an ordered Bi-Bi manner (i.e., UDP-Glucose binds to catalytic site of α CgT, and then cholesterol binds to another substrate binding site of the enzyme, thus forming CGL) (33). In the same study, we also demonstrated that CGL inhibits α CgT in presence of cholesterol in a mixed-type manner. Because of structural similarity between CGL and cholestenone (SI Appendix, Fig. S1), it is most possible that cholestenone inhibited α CgT in a mixed-type manner. Further study will be needed to address this problem.

Catabolic transformation of cholesterol to cholestenone requires oxidation of the 3 β -hydroxyl group, which is catalyzed by two different enzymes: cholesterol oxidase (ChOx) or 3 β -hydroxysteroid dehydrogenase (3 β -HsD) (18–20). ChOx and 3 β -HsD have been

isolated from bacteria such as *Bacteroides* sp., *Bacillus* spp., *Mycobacterium* sp., *Rhodococcus* spp., *Nocardia* sp., *Arthrobacter* sp., and *Pseudomonas* sp. Some strains of *E. coli*, *Eubacterium*, and *Bacteroides* isolated from humans produce cholestenone (16, 17), and *Bacteroides* is a major microbe in human gut microbiota (34). However, little is known about why cholesterol is converted to cholestenone in microorganisms, except that in *Myobacterium tuberculosis*, cholestenone may suppress the host immune responses (18). Importantly, cholestenone has few toxicological effects. In fact, Suzuki et al. demonstrated favorable effects of cholestenone on lipid metabolism, such as body weight control in mice, and reported that mice fed cholestenone are healthy without clinical abnormalities (35). Furthermore, there is no evidence that cholestenone is a mutagen (36).

We revealed that cholestenone alone administered orally to *H. pylori*-infected mice had an eradication effect (Fig. 5B). As yet, no drug has been reported to have eradication effects in vivo on *H. pylori* infection when given as a single agent. In this study, no attempt was made to detect cholestenone in the stomach of mice. However, since cholestenone is resistant to acid (37), it is thought to act stably against *H. pylori* in the stomach. For the clinical application of cholestenone, studies on dosage, administration period, and safety are needed. In the event that clinical use in humans is approved in the future, administration of cholestenone is expected to be as effective as antibiotics in eradicating *H. pylori*.

Strikingly, *H. pylori* growth suppression by cholestenone was also effective against a clinically isolated drug-resistant *H. pylori* strain. First-line triple therapy including amoxicillin, clarithromycin, and a PPI administered one week is used to treat *H. pylori* infection (38). However, this treatment fails in 17.2% of patients, mainly due to clarithromycin resistance (39). Thus, metronidazole is employed instead of clarithromycin as second-line triple therapy (40). However, 26.7% of those patients fail due to metronidazole resistance (39). In addition, *H. pylori* showing multidrug resistance is increasing




Fig. 5. Effects of orally administered cholestenone on *H. pylori*-infected mice. (A) Treatment schedule used to test effects of cholestenone diet in C57BL/6 mice infected with *H. pylori* (SS1 strain). *H. pylori* was administered orally a total of two times. (B) Copy numbers of the *H. pylori* αCgT gene present in 1 mg gastric mucosa. Boxes represent 25th to 75th percentile of copy numbers, and the horizontal line shows the median value. Whiskers represent 10th and 90th percentiles of copy numbers. Asterisk indicates a statistically significant difference (** $P < 0.01$). (C) Representative histopathology of the gastric mucosa of mice, with hematoxylin and eosin staining (Scale bar, 50 μm).

worldwide (41–43), and emergence of antibiotic-resistant *H. pylori* strains has led to reduced success with traditional treatments (44). Vivas et al. have proposed that if no new drug is developed to treat pathogenic bacteria by 2050, there will be no effective antibiotic available (45). Thus, new antibiotics having mechanisms distinct from traditional agents are required for *H. pylori* eradication. Our findings indicate that cholestenone is a potent candidate as an antibiotic for *H. pylori* including clarithromycin-resistant strain by suppressing CGL.

Materials and Methods

Bacterial Strains. A standard strain of *H. pylori* ATCC 43504 (46) and a mouse-adapted strain *H. pylori* SS1 (47) were used as described (12, 13, 48). Also used was the drug-resistant *H. pylori* “2460”, which was clinically isolated at Shinshu University Hospital, Matsumoto, Japan and stored at -80°C in Department of Laboratory Medicine in the same hospital.

Bacterial Growth Assay. Microbes (ATCC 43504, *H. pylori* “2460”, and *H. pylori* SS1) were preincubated in Brucella broth supplemented with 10% inactivated horse serum at 35°C in 15% CO_2 for 24 h, as described previously (49). After preincubation, *H. pylori* were subsequently cultured in 96-well plates in Mueller Hinton broth supplemented with various concentrations of cholesterol and analogs including fluorocholesterol (23-(dipyrrometheneboron difluoride)-24-norcholesterol; TopFluor Cholesterol), cholestenone, β -sitosterol, and cholestanol. Supplement concentrations were adjusted to 150 μM , 75 μM , 38 μM , 19 μM , 9 μM , and 4.7 μM by twofold serial dilutions. Microbes were cultured 4 d in 15% CO_2 at 35°C . Bacterial growth was measured based on OD at 600 nm (OD₆₀₀), and the absorbance of Mueller Hinton broth alone without microbes was measured at each time point as background. Horse serum was purchased from GIBCO/Life Technologies. Brucella broth was purchased from

Becton Dickinson. Mueller Hinton broth was purchased from Eiken Chemical. Cholesterol, cholestenone, and β -sitosterol were purchased from Wako Pure Chemical. Cholestanol was purchased from Toronto Research Chemicals. Top-Fluor Cholesterol was purchased from Avanti Polar Lipids.

Production of the CGL Polyclonal Antibody. CGL was purified from glycolipid fractions of the standard strain of *H. pylori* (ATCC43504) separated on a silica gel thin-layer chromatography plate using chloroform–methanol–water (70:30:5) solvent. A carboxy group was added to CGL by oxidation with KMnO_4 , followed by keyhole limpet hemocyanin (KLH) conjugation via amine coupling. In brief, 10 mg KLH was dissolved in 2.5 mL of 0.1 M 2-(*N*-morpholino) ethanesulfonic acid (MES, pH 6.0). An aliquot (5 mL) of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (8 mg) and 12 mg of *N*-hydroxysuccinimide dissolved in MES buffer (pH 6.0) was added to oxidized CGL and mixed for 15 min at room temperature (RT). Then, 2.5 mL KLH was added and the mixture allowed to react 2 h at RT. The oxidized CGL–KLH conjugate was dialyzed over 24 h in 1 L \times 4 of 0.15 M saline solution at 4°C . Subsequently, oxidized CGL–KLH was subcutaneously injected into two New Zealand White rabbits (SLC, Shizuoka, Japan) at weekly intervals three times, followed by additional injections given at 2 wk intervals, and animals were bled at 14 d after injection. Antisera were used without purification. The protocol for animal experiments was approved by the Animal Care Committee of Shinshu University and conducted in accordance with guidelines for use of laboratory animals at the same university (no. 200022).

Immunocytochemistry. A total 2 μL culture media of *H. pylori* (ATCC 43504 and “2460” strains) used for the bacterial growth assay (as described above) was obtained at each culture day, placed on Micro Slides Demarcation glass (Muto Pure Chemical), air dried, and heat fixed using a flame. Slides were incubated with anti-*H. pylori* antibody (DakoCytomation) or the anti-CGL antibody described above for 1 h at room temperature, anti-rabbit immunoglobulins

conjugated with horseradish peroxidase (HRP)-labeled polymer. A Histofine Simple Stain MAX-PO(R) Kit (Nichirei Biosciences, Tokyo, Japan) served as the secondary antibody. HRP activity was visualized using 3,3'-diaminobenzidine (Dajindo) with H₂O₂. As negative controls, primary antibodies were omitted from the immunocytochemistry procedure for *H. pylori* (ATCC 43504) incubated in Brucella broth supplemented with 10% inactivated horse serum at 35 °C in 15% CO₂ for 24 h; no specific staining was observed (Fig. 4B). In addition, anti-CGL antibody adsorbed with 0.75 μM of oxidized CGL as hapten was used for the same culture conditions of *H. pylori* (ATCC 43504), and no specific staining was noted (Fig. 4B).

Incorporation of Fluorescently Labeled Cholesterol. To verify that *H. pylori* growth requires exogenous cholesterol, *H. pylori* were cultured with fluorescent cholesterol (SI Appendix, Fig. S3). Specifically, after preincubation, bacteria were cultured in 96-well microtiter plates in Mueller Hinton broth supplemented with 150 μM of TopFluor cholesterol purchased from Avanti Polar Lipids. Cholesterol alone, purchased from Sigma-Aldrich, served as a positive control. Bacterial growth was measured as above. Incorporation of fluorescent cholesterol was observed by fluorescence microscopy at days 1, 2, and 4.

Preparation of Cholestenone/Cholesterol Mixtures. After preincubation, *H. pylori* (ATCC 43504 and "2460") were cultured in 96-well plates in Mueller Hinton broth supplemented with cholesterol, cholestenone, or both. Concentrations of cholesterol or cholestenone alone were 150 μM, 75 μM, 38 μM, 19 μM, 9 μM, and 4.7 μM. In analysis of mixtures, cholesterol concentrations were held constant at 150 μM, while cholestenone concentrations were 150 μM, 75 μM, 38 μM, 19 μM, 9 μM, and 4.7 μM. As controls, bacteria were also cultured in Mueller Hinton broth supplemented with 150 μM cholesterol. Bacterial growth was measured as above.

Thin-Layer Chromatography. Thin-layer chromatography was performed to evaluate αCG synthesis. After preincubation, *H. pylori* (ATCC 43504) were cultured 2 d in Mueller Hinton broth supplemented with 150 μM cholestenone or 150 μM cholesterol as a control. As a standard culture, *H. pylori* were also cultured in Brucella broth supplemented with 10% inactivated horse serum. After centrifugation, cell pellets were washed in saline. A total 5 mL chloroform:methanol (2:1) were added to pellets, and total lipids were extracted for 1 h at room temperature. Extracts were filtered, and 1 mL water was added, followed by removal of the aqueous layer. The remaining layer was dried under nitrogen and redissolved in chloroform:methanol (2:1). Purified lipids were separated on silica gel plates (Whatman, Maidstone, England), activated with a solvent of chloroform-methanol-water (16:8:1), and analyzed using orcinol sulfate.

Mice. C57BL/6J mice were purchased from Charles River Japan (Kanagawa, Japan) and maintained in autoclaved cages under specific pathogen-free conditions at the Animal Facility of Shinshu University, Matsumoto, Japan. Mice were bred until 10 wk of age. The protocol for animal experiments was approved by the Animal Care Committee of Shinshu University and conducted in accordance with guidelines for use of laboratory animals at the same university (no. 300022).

Cholestenone Diet. A 0.5% cholestenone mix based on AIN-93G and AIN-93G control diets used in the present study were purchased from Oriental Yeast. Specifically, chemically synthesized cholestenone was purchased from Wako Pure Chemical (catalog number 32-3190), and the purity measured by high-performance liquid chromatography was 98.9% (lot number DSH8741).

Then, cholestenone diet was prepared by uniformly mixing cholestenone to 0.5% in AIN-93G at Oriental Yeast. Both cholestenone and AIN-93G control diets sterilized by γ-ray irradiation were stored at 4 °C until the time of use.

Cholestenone Administration to *H. pylori*-Infected Mice. In total, 54 5-wk-old male mice were given a total of two oral doses of *H. pylori* SS1 every other day. Mice were fed the standard diet (MF, Oriental Yeast) for one week after infection, and then the diet was changed to the base diet AIN-93G for 27 mice (cholestenone [-] group) or the cholestenone-containing diet for the other 27 (cholestenone [+] group). Four weeks later, mice in both groups were killed by cervical dislocation, and stomachs were removed for quantitation of *H. pylori* ($n = 48$) and histological examination ($n = 6$).

qPCR. Stomachs from 48 mice (24 in the cholestenone [-] group and 24 in the cholestenone [+] group) were opened along the greater curvature. The gastric mucosa was scraped off with a glass slide, transferred to a sterile 1.5 mL tube, and the mucosal weight was measured (average 57 mg each). The gastric mucosa was gently homogenized, followed by extraction of genomic DNA using a High Pure PCR preparation Kit (Roche Diagnostics GmbH), according to the manufacturer's protocol. qPCR using SYBR Green I technology was performed using the 7300 Real-Time PCR System (Applied Biosystems) with the FastStart Universal SYBR Green Master (ROX) (Roche Diagnostics GmbH) as detection chemistry. The upstream and downstream primers designed to amplify *H. pylori* αCgT DNA for PCR were 5'-GGGCCT-GATGAGAAAAAATC-3' and 5'-GTCCGCTTAAAGGCTATT-3', respectively (50). Because the αCgT gene is unique to *H. pylori* and present as one copy per cell (14, 22, 23, 28), this assay estimates the number of *H. pylori* in mouse stomach. The master mix for each PCR run was prepared as follows: 2x Fast Start Universal SYBR Green Master (ROX), 300 nM each primer, 4.0 μL extracted genomic DNA, and then DNase-free water to a final volume of 50 μL. The amplification program included an initial denaturation step at 95 °C for 10 min, followed by 60 cycles with denaturation at 95 °C for 15 s, and annealing and elongation in one step at 60 °C for 1 min. At the end, the dissociation stage was performed as follows: 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s. Using a standard curve for αCgT gene in genomic DNA of *H. pylori* as described before (50, 51), copy number of αCgT gene was determined for each sample.

Histology. Stomachs from six mice (three in the cholestenone [-] group and three in the cholestenone [+] group) were opened along the greater curvature and fixed in 10% buffered formalin for 24 h at 4 °C. Each stomach was cut longitudinally into four pieces of equal width and collectively embedded in paraffin. Serial 3 μm sections were prepared from tissue blocks and subjected to hematoxylin and eosin staining.

Statistics. Statistical analysis was carried out using ystat2013 software (Igaku Tosho Shuppan). Significance was evaluated by Student's *t* test, Dunnett's test, or Mann-Whitney *U* test. All parametric data are presented as means ± SE, and nonparametric data are presented as percentile. A value of $P < 0.05$ was considered significant.

Data Availability. All study data are included in the article and/or SI Appendix.

ACKNOWLEDGMENTS. We thank Dr. Elise Lamar for editing the manuscript and Dr. Eriko Kasuga for providing *H. pylori* "2460" strain. This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Sciences, Nos. 16K08708 and 18K08419 (M.K.) and 19H03441 (J.N.).

1. J. Parsonnet, *Helicobacter pylori*. *Infect. Dis. Clin. North Am.* **12**, 185–197 (1998).
2. B. Marshall, *Helicobacter pylori*: 20 years on. *Clin. Med. (Lond.)* **2**, 147–152 (2002).
3. S. Suerbaum, P. Michetti, *Helicobacter pylori* infection. *N. Engl. J. Med.* **347**, 1175–1186 (2002).
4. R. M. Peek Jr, J. E. Crabtree, *Helicobacter* infection and gastric neoplasia. *J. Pathol.* **208**, 233–248 (2006).
5. N. Uemura *et al.*, *Helicobacter pylori* infection and the development of gastric cancer. *N. Engl. J. Med.* **345**, 784–789 (2001).
6. K. Fukase *et al.*; Japan Gast Study Group, Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. *Lancet* **372**, 392–397 (2008).
7. M. Ruge *et al.*, Gastric cancer as preventable disease. *Clin. Gastroenterol. Hepatol.* **15**, 1833–1843 (2017).
8. A. O'Connor, J. P. Gisbert, D. McNamara, C. O'Morain, Treatment of *Helicobacter pylori* infection 2010. *Helicobacter* **15**, 46–52 (2010).
9. N. R. O'Morain, M. P. Dore, A. J. P. O'Connor, J. P. Gisbert, C. A. O'Morain, Treatment of *Helicobacter pylori* infection in 2018. *Helicobacter* **23**, e12519 (2018).
10. J. Luther *et al.*, Empiric quadruple vs. triple therapy for primary treatment of *Helicobacter pylori* infection: Systematic review and meta-analysis of efficacy and tolerability. *Am. J. Gastroenterol.* **105**, 65–73 (2010).
11. Y. Hirai *et al.*, Unique cholesteryl glucosides in *Helicobacter pylori*: Composition and structural analysis. *J. Bacteriol.* **177**, 5327–5333 (1995).
12. M. Kawakubo *et al.*, Natural antibiotic function of a human gastric mucin against *Helicobacter pylori* infection. *Science* **305**, 1003–1006 (2004).
13. H. Hoshino *et al.*, Membrane-associated activation of cholesterol α-glucosyltransferase, an enzyme responsible for biosynthesis of cholesteryl-α-D-glucopyranoside in *Helicobacter pylori* critical for its survival. *J. Histochem. Cytochem.* **59**, 98–105 (2011).
14. J. F. Tomb *et al.*, The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature* **388**, 539–547 (1997).
15. A. Marais, G. L. Mendz, S. L. Hazell, F. Mégraud, Metabolism and genetics of *Helicobacter pylori*: The genome era. *Microbiol. Mol. Biol. Rev.* **63**, 642–674 (1999).

16. I. A. Macdonald, V. D. Bokkenheuser, J. Winter, A. M. McLernon, E. H. Mosbach, Degradation of steroids in the human gut. *J. Lipid Res.* **24**, 675–700 (1983).
17. P. Gérard, Metabolism of cholesterol and bile acids by the gut microbiota. *Pathogens* **3**, 14–24 (2013).
18. J. Kreit, Microbial catabolism of sterols: Focus on the enzymes that transform the sterol 3 β -hydroxy-5-en into 3-keto-4-en. *FEMS Microbiol. Lett.* **364**, fnx007 (2017).
19. V. Giorgi, P. Menéndez, C. García-Carnelli, Microbial transformation of cholesterol: Reactions and practical aspects—an update. *World J. Microbiol. Biotechnol.* **35**, 131 (2019).
20. S. B. Mahato, S. Garai, Advances in microbial steroid biotransformation. *Steroids* **62**, 332–345 (1997).
21. E. Hidaka *et al.*, Helicobacter pylori and two ultrastructurally distinct layers of gastric mucous cell mucins in the surface mucous gel layer. *Gut* **49**, 474–480 (2001).
22. A. H. Lebrun *et al.*, Cloning of a cholesterol- α -glucosyltransferase from Helicobacter pylori. *J. Biol. Chem.* **281**, 27765–27772 (2006).
23. H. Lee *et al.*, Expression cloning of cholesterol α -glucosyltransferase, a unique enzyme that can be inhibited by natural antibiotic gastric mucin O-glycans, from Helicobacter pylori. *Biochem. Biophys. Res. Commun.* **349**, 1235–1241 (2006).
24. M. Kawakubo *et al.*, Cholesterol- α -glucosyltransferase gene is present in most Helicobacter species including gastric non-Helicobacter pylori helicobacters obtained from Japanese patients. *Helicobacter* **23**, e12449 (2018).
25. F. Mégraud, Resistance of Helicobacter pylori to antibiotics. *Aliment. Pharmacol. Ther.* **11**, 43–53 (1997).
26. J. M. Whitmire, D. S. Merrell, Successful culture techniques for Helicobacter species: General culture techniques for Helicobacter pylori. *Methods Mol. Biol.* **921**, 17–27 (2012).
27. M. A. Qaria *et al.*, Roles of cholesteryl- α -glucoside transferase and cholesteryl glucosides in maintenance of Helicobacter pylori morphology, cell wall integrity, and resistance to antibiotics. *mBio* **9**, e01523-18 (2018).
28. R. A. Alm *et al.*, Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. *Nature* **397**, 176–180 (1999).
29. T. T. Binh, R. Suzuki, D. H. Kwon, Y. Yamaoka, Complete genome sequence of a metronidazole-resistant Helicobacter pylori strain. *Genome Announc.* **3**, e00051-15 (2015).
30. Y. Ito *et al.*, Helicobacter pylori cholesteryl α -glucosides contribute to its pathogenicity and immune response by natural killer T cells. *PLoS One* **8**, e78191 (2013).
31. L. P. Andersen, L. Rasmussen, Helicobacter pylori-coccoid forms and biofilm formation. *FEMS Immunol. Med. Microbiol.* **56**, 112–115 (2009).
32. K. A. Eaton, C. E. Catrenich, K. M. Makin, S. Krakowka, Virulence of coccoid and bacillary forms of Helicobacter pylori in gnotobiotic piglets. *J. Infect. Dis.* **171**, 459–462 (1995).
33. H. Lee *et al.*, Alpha1,4GlcNAc-capped mucin-type O-glycan inhibits cholesterol alpha-glucosyltransferase from Helicobacter pylori and suppresses H. pylori growth. *Glycobiology* **18**, 549–558 (2008).
34. I. Sekirov, S. L. Russell, L. C. Antunes, B. B. Finlay, Gut microbiota in health and disease. *Physiol. Rev.* **90**, 859–904 (2010).
35. K. Suzuki, T. Shimizu, T. Nakata, The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice. *Bioorg. Med. Chem. Lett.* **8**, 2133–2138 (1998).
36. A. M. Wolfreys, P. A. Hepburn, Safety evaluation of phytosterol esters. Part 7. Assessment of mutagenic activity of phytosterols, phytosterol esters and the cholesterol derivative, 4-cholesten-3-one. *Food Chem. Toxicol.* **40**, 461–470 (2002).
37. A. I. Rushdi, G. Ritter, J. O. Grimalt, B. R. T. Simoneit, Hydrous pyrolysis of cholesterol under various conditions. *Org. Geochem.* **34**, 799–812 (2003).
38. J. J. Misiewicz *et al.*; Lansoprazole Helicobacter Study Group, One week triple therapy for Helicobacter pylori: A multicentre comparative study. *Gut* **41**, 735–739 (1997).
39. V. De Francesco *et al.*, Worldwide H. pylori antibiotic resistance: A systematic review. *J. Gastrointest. Liver Dis.* **19**, 409–414 (2010).
40. K. Murakami *et al.*, Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. *Aliment. Pharmacol. Ther.* **17**, 119–123 (2003).
41. N. Rezaeiamesh, N. Farzi, S. Pirmanesh, S. Emami, A. Yadegar, Management of multi-drug resistant Helicobacter pylori infection by supplementary, complementary and alternative medicine; A review. *Gastroenterol. Hepatol. Bed Bench* **10**, S8–S14 (2017).
42. E. Tacconelli *et al.*; WHO Pathogens Priority List Working Group, Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* **18**, 318–327 (2018).
43. L. Boyanova, P. Hadzhiyski, N. Kandilarov, R. Markovska, I. Mitov, Multidrug resistance in Helicobacter pylori: Current state and future directions. *Expert Rev. Clin. Pharmacol.* **12**, 909–915 (2019).
44. C. A. Fallone *et al.*, The Toronto consensus for the treatment of Helicobacter pylori infection in adults. *Gastroenterology* **151**, 51–69.e14 (2016).
45. R. Vivas, A. A. T. Barbosa, S. S. Dolabela, S. Jain, Multidrug-resistant bacteria and alternative methods to control them: An overview. *Microb. Drug Resist.* **25**, 890–908 (2019).
46. C. S. Goodwin *et al.*, Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively. *Int. J. Syst. Bacteriol.* **39**, 397–405 (1989).
47. A. Lee *et al.*, A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain. *Gastroenterology* **112**, 1386–1397 (1997).
48. B. N. Benoit *et al.*, Role of ASC in the mouse model of Helicobacter pylori infection. *J. Histochem. Cytochem.* **57**, 327–338 (2009).
49. M. Kawakubo, Y. Ito, M. Fukuda, J. Nakayama, “Helicobacter pylori” in *Glycoscience: Biology and Medicine*, N. Taniguchi, T. Endo, G. Hart, P. Seeberger, C. H. Wong, Eds. (Springer, Japan, Tokyo, 2015), pp. 723–729.
50. M. Kawakubo *et al.*, Cloning of Helicobacter suis cholesterol α -glucosyltransferase and production of an antibody capable of detecting it in formalin-fixed, paraffin-embedded gastric tissue sections. *Histochem. Cell Biol.* **148**, 463–471 (2017).
51. M. A. Providenti, J. M. O'Brien, R. J. Ewing, E. S. Paterson, M. L. Smith, The copy-number of plasmids and other genetic elements can be determined by SYBR-Green-based quantitative real-time PCR. *J. Microbiol. Methods* **65**, 476–487 (2006).